von Allmen E, Rieben R, Nydegger UE. 1994. Development of a C1q-ABO-ELISA to measure
C1q binding by human anti-A alloantibodies. J Immunol Methods 171:85-92.
Rieben R, Korchagina EY, von Allmen E, Kremer Hovinga J, Lämmle B, Jungi TW, Bovin NV,
Nydegger UE. 1995. In vitro evaluation of the efficacy and biocompatibility of new, synthetic ABO
immunoabsorbents. Transplantation 60(5):425-430.
Rieben R, von Allmen E, Korchagina EY, Nydegger UE, Neethling FA, Kujundzic M, Koren E,
Bovin NV, Cooper DKC. 1995. Detection, immunoabsorption, and inhibition of cytotoxic activity of
anti-alpha Gal antibodies using newly developed substances with synthetic Gal alpha1-3 Gal
disaccharide epitopes. Xenotransplantation 2:98-106.
Uetz-von Allmen E, Sturzenegger M, Rieben R, Rihs F, Frauenfelder A, Nydegger UE. 1998.
Antiganglioside GM1 antibodies and their complement activating capacity in central and peripheral
nervous system disorders and in controls. Europ Neurol 39(2):103-110.
Hari Y, von Allmen EC, Boss GM, Naiem A, Gittermann M, Nydegger UE. 1998. The complement
activating capacity of maternal IgG antibodies to blood group A in paired mother/child serum
samples. Vox Sang 74(2):95-100.
Waeckerle-Men Y, Scandella E, Uetz-von Allmen E, Ludewig B, Gillessen S, Merkle HP, Gander
B, Groettrup M. 2004. Phenotype and functional analysis of human monocyte-derived dendritic
cells loaded with biodegradable poly(lactide-co-glycolide) microspheres for immunotherapy. J Immunol Methods 287:109-124.
Waeckerle-Men Y, Uetz-von Allmen E, von Moos R, Classon BJ, Scandella E, Schmid HP,
Ludewig B, Groettrup M, Gillessen S. 2005. Dendritic cells generated from patients with androgen-independent prostate cancer are not impaired in migration and T-cell stimulation. Prostate 64(4):323-331.
Waeckerle-Men Y, Uetz-von Allmen E, Gander B, Scandella E, Schlosser E, Schmidtke G, Merkle HP, Groettrup M. 2006. Encapsulation of proteins and peptides into biodegradable poly(D,L-lactide-co-glycolide) microspheres prolongs and enhances antigen presentation by human dendritic cells. Vaccine 24(11):1847-1857.
Waeckerle-Men Y, Uetz-von Allmen E, Fopp M, von Moos R, Boehme C, Schmid HP, Ackermann D, Cerny T, Ludewig B, Groettrup M, Gillessen S. 2006. Dendritic cell-based multi-epitope immunotherapy of hormone-refractory prostate carcinoma. Cancer Immunol Immunother 55(12):1524-33. Epub 2006 Apr 13
Fischer S, Uetz-von Allmen E, Waeckerle-Men Y, Groettrup M, Merkle HP, Gander B. 2007. The preservation of phenotype and functionality of dendritic cells upon phagocytosis of polyelectrolyte-coated PLGA microparticles. Biomaterials 28:994-1004.
Uetz-von Allmen E, Koch M, Fritz G, Legler DF. 2008. V domain of RAGE interacts with AGEs on prostate carcinoma cells. Prostate 68:748-758.
Legler DF, Bruckner M, Uetz-von Allmen E, Krause P. 2010. Prostaglandin E(2) at new glance: Novel insights in functional diversity offer therapeutic chances. Int J Biochem Cell Biol 42(2):198-201.
